Truist analyst Samuel Brodovsky downgraded Vericel to Hold from Buy with a price target of $22, down from $30, arguing that the company’s lower full-year guidance "overshadows" its MACI revenue beat in Q3. Brodovsky lowered his estimates and "struggles to argue for valuation upside" until he has more confidence in a growth reacceleration.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VCEL:
